European Journal of Cancer
Volume 42, Issue 12 , Pages 1889-1896 , August 2006

Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer

  • Mads Nikolaj Holten-Andersen

      Affiliations

    • The Institute of Veterinary Patobiology, The Royal Veterinary and Agricultural University, Ridebanevej 9, 1870 Frederiksberg, Denmark
    • The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author: Tel.: +45 352 83130; fax: +45 353 53514.
    • ,
  • Hans Jørgen Nielsen

      Affiliations

    • Department of Surgical Gastroenterology, Hvidovre University Hospital, Copenhagen, Denmark
    • ,
  • Steen Sørensen

      Affiliations

    • Department of Clinical Biochemistry, Hvidovre University Hospital, Copenhagen, Denmark
    • ,
  • Vibeke Jensen

      Affiliations

    • The Institute of Veterinary Patobiology, The Royal Veterinary and Agricultural University, Ridebanevej 9, 1870 Frederiksberg, Denmark
    • The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Nils Brünner

      Affiliations

    • The Institute of Veterinary Patobiology, The Royal Veterinary and Agricultural University, Ridebanevej 9, 1870 Frederiksberg, Denmark
    • ,
  • Ib Jarle Christensen

      Affiliations

    • The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark
    • Department of Surgical Gastroenterology, Hvidovre University Hospital, Copenhagen, Denmark

Received 15 September 2005 ,Revised 24 December 2005 ,Accepted 13 January 2006.

References 

  1. Midgley R, Kerr D. Colorectal cancer. Lancet. 1999;353:391–399
  2. Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet. 2000;355:395–399
  3. Benson AB, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18:3586–3588
  4. Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718–727
  5. Safi F, Link KH, Beger HG. Is follow-up of colorectal cancer patients worthwhile?. Dis Colon Rectum. 1993;36:636–643
  6. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418
  7. Welgus HG, Jeffrey JJ, Eisen AZ, Roswit WT, Stricklin GP. Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res. 1985;5:167–179
  8. Birkedal HH, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197–250
  9. Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66–69
  10. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298:29–32
  11. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat. 1999;54:235–244
  12. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest. 1998;102:2002–2010
  13. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59:6267–6275
  14. Rhee JS, Diaz R, Korets L, Hodgson JG, Coussens LM. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res. 2004;64:952–961
  15. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–536
  16. Fong KM. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res. 1996;2:1369–1372
  17. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997;3:1623–1628
  18. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer. 1991;49:666–672
  19. Holten-Andersen MN, Murphy G, Nielsen HJ, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer. 1999;80:495–503
  20. Holten-Andersen MN, Christensen IJ, Nielsen HJ, et al. Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res. 2002;8:156–164
  21. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6:4292–4299
  22. Holten-Andersen MN, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival. a validation study. Eur J Cancer. 2004;40:64–72
  23. Nielsen HJ, McArdle CS, Moesgaard F. The effect of ranitidine on long term survival in primary colorectal cancer. Gastrointestinal Cancer. 1998;2:227–233
  24. Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol. 1932;35:323–332
  25. Hembry RM, Murphy G, Reynolds JJ. Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. J Cell Sci. 1985;73:105–119
  26. Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M, Docherty AJ. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry. 1991;30:8097–8102
  27. Cooksley S, Hipkiss JB, Tickle SP, et al. Immunoassays for the detection of human collagenase, stromelysin, tissue inhibitor of metalloproteinases (TIMP) and enzyme-inhibitor complexes. Matrix. 1990;10:285–291
  28. Babson AL. The Cirrus IMMULITE: a new random access automated immunoassay system. J Clin Immunoassay. 2000;14:83–88
  29. Michel P, Merle V, Chiron A, et al. Postoperative management of stage II/III colon cancer: a decision analysis. Gastroenterology. 1999;117:784–793
  30. Andersen PK, Vaeth M. Simple parametric and nonparametric models for excess and relative mortality. Biometrics. 1989;45:523–535

PII: S0959-8049(06)00348-0

doi: 10.1016/j.ejca.2006.01.058

European Journal of Cancer
Volume 42, Issue 12 , Pages 1889-1896 , August 2006

Article Tools

* Image Usage & Resolution